Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.73 |
| ▸ | MAOB | P27338 | 5/20 | 0.73 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31668688 | 0.94 | MAOA (0.66) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL31668675 | 0.92 | NPC1 (0.64) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL22803696 | 0.92 | NPC1 (0.67) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL27375907 | 0.88 | NPC1 (0.61) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL25120815 | 0.85 | NPC1 (0.57) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL22803277 | 0.84 | MAOB (0.59) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL4347943 | 0.83 | NPC1 (0.69) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL22803834 | 0.83 | DDX3X (0.61) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL22803836 | 0.83 | NPC1 (0.58) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL22803833 | 0.83 | NPC1 (0.58) | MAOAMAOBNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064358-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | FREDERICKSON MARTYN (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1495016-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | Astex Technology Limited (GB) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087087-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | ASTEX TECHNOLOGY LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | MAPK1, IDO1, INMT | MAOA 79/4885MAOB 103/4885NPC1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.